HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

befetupitant

orally active neurokinin-1 receptor antagonist; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - befetupitant: 1

Experts

1.	Aramini, Andrea: 1 article (09/2014)
2.	Bignami, Fabio: 1 article (09/2014)
3.	Ferrari, Giulio: 1 article (09/2014)
4.	Giacomini, Chiara: 1 article (09/2014)
5.	Lorusso, Anna: 1 article (09/2014)
6.	Rama, Paolo: 1 article (09/2014)

Related Diseases

1.	Corneal Neovascularization 09/16/2014 - "To determine whether the inhibition of Substance P (SP) activity can reduce corneal neovascularization (CNV) by means of local administration of high-affinity, competitive, tachykinin 1 receptor (NK1R) antagonists Lanepitant and Befetupitant. "
2.	Burns 09/16/2014 - "Finally, topical application of Befetupitant reduced CNV in the alkali burn model but was toxic owing to the vehicle (dimethyl sulfoxide [DMSO]); hence, Befetupitant was not tested in the suture model. "

Related Drugs and Biologics

1.	Tachykinins
2.	Substance P
3.	Dimethyl Sulfoxide (DMSO)
4.	Alkalies
5.	1- (N- (2- methoxybenzyl)acetylamino)- 3- (1H- indol- 3- yl)- 2- (N- (2- (4- (piperidin- 1- yl)piperidin- 1- yl)acetyl)amino)propane (Lanepitant)

Related Therapies and Procedures

1.	Sutures (Suture)